Stock GLYC GLYCOMIMETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.271 USD -1.09% Intraday chart for GlycoMimetics, Inc. +0.37% -88.52%
May. 09 GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50 MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed, Refractory Acute Myeloid Leukemia on June 4, 2024
AQ
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
BU
GlycoMimetics: Q1 Earnings Snapshot
AQ
GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50
MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading
MT
Sector Update: Health Care
MT
GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint
MT
Transcript : GlycoMimetics, Inc., Q1 2024 Earnings Call, May 06, 2024
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
BU
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia
CI
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
BU
Transcript : GlycoMimetics, Inc., Q4 2023 Earnings Call, Mar 27, 2024
GlycoMimetics: Q4 Earnings Snapshot
AQ
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
BU
GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
GlycoMimetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stocks Edge -2-
DJ
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
BU
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLYC Stock
  4. News GlycoMimetics, Inc.